Meeting
2014 ASCO Annual Meeting
Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%.
Authors
Youn H. Kim
Stanford Cancer Institute, Stanford, CA
Youn H. Kim , Madeleine Duvic , Joan Guitart , Stuart Lessin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT00535470
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9093)
DOI
10.1200/jco.2014.32.15_suppl.9093
Abstract #
9093
Poster Bd #
297
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2024 ASCO Annual Meeting
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).
First Author: Bradley Alexander McGregor
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns